曲美他嗪治疗缺血性心肌病心衰的疗效及对心功能和心率变异性的影响被引量：3

Trimetazidine Treatment of Ischemic Cardiomyopathy Heart Failure Efficacy and Effects on Heart Function and Heart Rate Variability

暂未订购

导出

摘要目的探讨曲美他嗪治疗缺血性心肌病心衰的临床疗效及对患者心功能和心率变异性的影响。方法将124例缺血性心肌病心衰患者按照就诊顺序随机分为对照组和观察组各62例。两组均采用常规抗心衰治疗,观察组在此基础上加用曲美他嗪,观察两组治疗前后心功能及心率变异性差异,并对两组的临床疗效进行评价。结果观察组总有效率为93.55%,显著高于对照组(P<0.05);两组治疗后心功能和心率变异性均明显改善,观察组变化更为显著,两组间差异具有统计学意义(P<0.05)。结论曲美他嗪治疗缺血性心肌病心衰疗效确切,能够有效改善患者心功能及心率变异性,值得大力推广。

作者郑巧文

机构地区福清市医院心内科

出处《现代诊断与治疗》 CAS 2015年第4期751-753,共3页 Modern Diagnosis and Treatment

关键词曲美他嗪心力衰竭心率变异性

分类号 R542.2 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献5

1黄小春.曲美他嗪对缺血性心力衰竭患者心率变异性的影响[J].中西医结合心脑血管病杂志,2012,10(9):1033-1034. 被引量：10
2郝冬琴,宋付凯,韩文杰,刘恒亮,赵友民.曲美他嗪联合瑞舒伐他汀治疗缺血性心肌病心力衰竭的疗效[J].中国老年学杂志,2012,32(15):3152-3153. 被引量：48
3沈惠珉.曲美他嗪在缺血性心肌病心力衰竭治疗中的疗效评价[J].海峡药学,2013,25(4):152-153. 被引量：10
4文凤珠.曲美他嗪治疗缺血性心肌病心衰62例临床疗效观察[J].中外医学研究,2012,10(18):15-16. 被引量：9
5欧艳勉.曲美他嗪对缺血性心肌病心衰患者心功能及心率变异性的影响[J].中国医药导报,2012,9(18):90-91. 被引量：24

二级参考文献41

1Candia AM,Villacorta H Jr,Mesquita ET.Immune-inflammatory activa-tion in heart failure(J).Arq Bras Cardiol,2007;89(3):183-90.
2YangY,Mou Y,Hu SJ,et al.Beneficial effect of rosuvastatin on cardiac dysfunction is associated with alterations incalcium-regulatory proteins(J).Eur J Heart Fail,2009;11(1):6-13.
3ZacaV,Rastogi S,Imai M,et al.Chronic monotherapy with rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure(J).J Am Coll Cardiol,2007;50(6):551-7.
4LiaoJK.Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a re-duc-tase inhibition beyond low-density lipoprotein cholesterol(J).Am J Cardiol,2005;96(5):24-33.
5McClellan KJ,Plosker GL.Trimetazidine.A review of its use in stable an-gina pectoris and other coronary conditions(J).Drugs,1999;58(1):143-57.
6Gambert S,Vergely C,Filomenko R,et al.Adverse effects of free fatty acid associated with increased oxidative stressin postischemic isolated rat hearts(J).Mol Cell Biochem,2006;283(1-2):147-52.
7Monteiro P,Duarte AI,Goncalves LM,et al.Protective effect of trimetazi-dine on myocardial mitochondrial function inan ex-vivo model of global myocardial ischemia(J).Eur J Pharmacol,2004;503(1-3):123-8.
8Kantor PF,Lucien A,Kozak R,et al.The antianginal drug tri-metazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxi-dation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thio-lase(J).Circ Res,2000;86(5):580-8.
9KhanM,Meduru S,Mostafa M,et al.Trimetazidine,administered at the onset of reperfusion,ameliorates myocardial dysfunction and injury by ac-tivation of p38 mitogen-activated protein kinase and Akt signaling(J).J Pharmacol Exp Ther,2010;333:421-9.
10Boogers MJ , Veltman CE, Bax JJ. Cardiac autonomic nervous sys -tern in heart failure: Imaging technique and clinical implicaiions[J]. Curr Cardiol Rev,2011,7(1) : 35 - 42.